Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
Authors:
Open Access
Abstract
Aims Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. Unbound/loosely bound tissue copper II ions are powerful catalysts of oxidative stress and inhibitors of antioxidants. Trientine is a highly selective copper II chelator. In preclinical and clinical studies in diabetes, trientine is associated with reduced LVH and fibrosis, and improved mitochondrial function and energy metabolism. Trientine was associated with improvements in cardiac structure and function in an open-label study in patients with HCM. Methods The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy (TEMPEST) trial is a multicentre, double-blind, parallel group, 1:1 randomised, placebo-controlled phase II trial designed to evaluate the efficacy and mechanism of action of trientine in patients with HCM. Patients with a diagnosis of HCM according to the European Society of Cardiology Guidelines and in New York Heart Association classes I–III are randomised to trientine or matching placebo for 52 weeks. Primary outcome is change in left ventricular (LV) mass indexed to body surface area, measured using cardiovascular magnetic resonance. Secondary efficacy objectives will determine whether trientine improves exercise capacity, reduces arrhythmia burden, reduces cardiomyocyte injury, improves LV and atrial function, and reduces LV outflow tract gradient. Mechanistic objectives will determine whether the effects are mediated by cellular or extracellular mass regression and improved myocardial energetics. Conclusion TEMPEST will determine the efficacy and mechanism of action of trientine in patients with HCM. Trial registration numbers NCT04706429 and ISRCTN57145331.Keywords
Funding Information
- Efficacy and Mechanism Evaluation Programme (NIHR127575)
- National Institute for Health and Care Research (Advanced Fellowship (NIHR300867), Advanced Fellowship (NIHR301338), Leicester Biomedical Research Centre, NIHR Biomedical Research Centre (NIHR203308), Oxford NIHR Biomedical Research Centre)
- Slovak Grant Agencies VEGA ((2/0003/20), APVV (19-0032))
- British Heart Foundation (AA/18/4/34221, British Heart Foundation Accelerator Award)
- BHF Centre of Research Excellence, Oxford (RE/18/3/34214)
- Wellcome Trust (221805/Z/20/Z, Sir Henry Dale Fellowship)
- British Heart Foundation ((FS/CRTF/21/24144))
This publication has 28 references indexed in Scilit:
- Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic ratsCardiovascular Diabetology, 2013
- Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairmentCardiovascular Diabetology, 2013
- Mechanisms of disease: hypertrophic cardiomyopathyNature Reviews Cardiology, 2011
- Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs DiseaseDrugs, 2011
- Research Priorities in Hypertrophic CardiomyopathyCirculation, 2010
- Reversal of diabetes‐evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)‐selective chelatorProteomics – Clinical Applications, 2007
- Molecular Changes Evoked by Triethylenetetramine Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic RatsMolecular Pharmacology, 2006
- Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic CardiomyopathyCirculation, 2006
- Copper, oxidative stress, and human healthMolecular Aspects of Medicine, 2005
- Role of Oxidative Stress in Myocardial Hypertrophy and FailureJournal of Molecular and Cellular Cardiology, 2002